The first short-term phase 2 prospective study (NCT00237380) was performed on 24 adults (aged 18 to 56) suffering from CF (characterized by the presence of two disease-causing CFTR mutations, with at least one being nonsense) and taking neither systematic nor inhaled aminoglycosides. This evidence concerns the gene CFTR and cystic fibrosis.